MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1136/heartjnl-2025-327720

Медицинская библиотека · Heart (British Cardiac Society) · 2026

Optimal duration of dual antiplatelet therapy in ischaemic heart disease: a systematic review and network meta-analysis of randomised controlled trials.

Fujii Toshiharu, Kasai Satoshi, Kawamura Yota, Okutsu Masaaki, Yoshimachi Fuminobu, Ikari Yuji

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Shorter dual antiplatelet therapy (DAPT) regimens may offer a more favourable risk-benefit profile compared with longer treatment. The aim of this study was to determine the optimal duration by assessing net adverse clinical events (NACE).

METHODS

We searched for randomised controlled trials that compared clinical outcomes of different DAPT durations in patients with ischaemic heart disease from Medline, Scopus and the Cochrane Library. A network meta-analysis was subsequently conducted for DAPT durations of 1 month, 3 months, 6 months, 12 months and >12 months. The primary outcome was defined as NACE, a composite of death, myocardial infarction, stroke, stent thrombosis and bleeding events. Individual components of NACE served as secondary outcomes. Five DAPT durations were ranked for each outcome using surface under the cumulative ranking.

RESULTS

This analysis included 31 randomised controlled trials comprising 95 910 patients. 1-month DAPT was associated with a significantly lower risk of NACE compared with 3-month, 6-month, 12-month and >12 month DAPT (risk ratio (CI): 0.74 (0.58 to 0.93); 0.63 (0.50 to 0.80); 0.64 (0.53 to 0.78); and 0.67 (0.51 to 0.87), respectively). There were no significant differences in death, myocardial infarction, stroke or stent thrombosis with 1-month DAPT, except for a higher risk of myocardial infarction compared with >12 month DAPT (risk ratio (CI): 1.53 (1.02 to 2.30)). Notably, 1-month DAPT was associated with a significantly lower risk of bleeding events compared with 12-month and >12 month DAPT (risk ratio (CI): 0.57 (0.40 to 0.83) and 0.47 (0.29 to 0.77), respectively). The SUCRA value for NACE was the highest for the 1-month regimen (99.8, 65.4, 24.6, 21.9 and 38.3 for 1 month, 3 months, 6 months, 12 months and >12 months, respectively).

CONCLUSIONS

1-month DAPT may offer the lowest risk balance between ischaemic and bleeding risks; however, these findings should be applied within an individualised, patient-specific risk management framework.

Для цитирования: Fujii Toshiharu, Kasai Satoshi, Kawamura Yota, Okutsu Masaaki, Yoshimachi Fuminobu, Ikari Yuji. Optimal duration of dual antiplatelet therapy in ischaemic heart disease: a systematic review and network meta-analysis of randomised controlled trials.. Heart (British Cardiac Society). 2026. DOI: 10.1136/heartjnl-2025-327720.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.